Renowned Biomedical Scientist Franco Cavaleri Challenges Conventional Alzheimer's Theories in Groundbreaking Study
VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- Franco Cavaleri, B.Sc., Ph.D.c, a distinguished biomedical research scientist and CEO of Biologic Pharmamedical Research and Manufacturing, has published a pioneering study that reexamines the role of amyloid β-peptides (Aβ) in Alzheimer's disease (AD). This research, featured in Frontiers in Neuroscience, proposes a paradigm shift in understanding the function of Aβ, suggesting they may serve a protective role against metal toxicity in the brain rather than being primary culprits in AD progression.
A Protective Perspective on Amyloid β-Peptides
Alzheimer's disease has long been associated with the accumulation of amyloid plaques, leading to the prevailing belief that Aβ contributes directly to neurodegeneration. Cavaleri's study challenges this notion by presenting evidence that Aβ and the enzyme β-secretase (BACE1) are integral to a cellular defense mechanism aimed at sequestering harmful metal ions. This chelation process may prevent oxidative stress and neuronal damage by neutralizing metal-induced toxicity. It is only when this protective system becomes overwhelmed by excessive metal exposure that neurodegenerative symptoms emerge.
Implications for Alzheimer's Research and Treatment
This groundbreaking perspective opens new avenues for Alzheimer's research, emphasizing the need to explore environmental factors, such as metal exposure, in disease development. By shifting the focus from solely targeting Aβ for therapeutic intervention to understanding its protective functions, scientists can develop more effective strategies that address the root causes of neurodegeneration.
Franco Cavaleri: A Leader in Biomedical Innovation
Franco Cavaleri's extensive background in nutritional biochemistry and natural medicine pharmacology has positioned him at the forefront of biomedical research. As CEO and Research Director of Biologic Pharmamedical Research and Manufacturing, Cavaleri has dedicated his career to bridging the gap between natural health products and pharmaceutical science. His work has led to significant advancements in understanding inflammation, neurodegenerative diseases, and the pharmacology of natural compounds.
Beyond his groundbreaking research, Franco Cavaleri is the best-selling author and host of the Potential Within podcast, and a former IFBB Mr. North America Bodybuilding Champion. His powerful personal story—overcoming severe ulcerative colitis without surgery through targeted natural medicine and science-backed supplementation—fuels his mission to transform modern health care. Through innovations like his patented Curcumin BioBDMC30™, Ashwith™ Ashwagandha, Keto BHB-BA™, and Glyvia™ sweetener (among over 15 other patents), Cavaleri is redefining what proactive health looks like. His integrative approach fuses rigorous biomedical science with holistic lifestyle and nutraceutical interventions, offering a sustainable solution to an overburdened healthcare system. By empowering individuals to take control of their health through nutrition, precision supplementation, and evidence-based self-care, Cavaleri's work aims not only to reduce dependency on conventional medicine—but to enable longer, healthier, and more vibrant lives.
About Biologic Pharmamedical Research and Manufacturing
Biologic Pharmamedical Research and Manufacturing, based in Vancouver, Canada with manufacturing facilities in both Canada and the USA, specializes in the research and development of evidence-based nutraceuticals and pharmaceuticals. Under Cavaleri's leadership, the company focuses on innovative solutions that merge natural medicine with modern pharmacological principles to address complex health challenges as well as prevention. BiologicPharmaMedical
Access the Full Study
For a comprehensive understanding of this transformative research, the full study is available at Frontiers in Neurology.
Media Contact
Christina Weizmann
Communications Lead
Phone: 604.684.9321
Email: christina.w@biologic-med.com
Business Development Contact
Mike Schmidt
VP Business & Product Development
Phone: 1.855.518.8858
Email:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Montreal Gazette
4 days ago
- Montreal Gazette
Opinion: Canada is falling behind on treatments for Alzheimer's disease
Op Eds Alzheimer's disease is an insidious and relentless loss of memory and thinking, accompanied by a gradual yet devastating deterioration in ability to function independently. It's a terrifying diagnosis for patients and families alike. Dementia is defined as a loss of memory or thinking, which takes away daily independence. Alzheimer's disease is the buildup of amyloid and tau proteins in the brain — proteins that begin as helpful, yet become toxic as they accumulate. Alzheimer's disease is therefore the cause, and dementia is the effect. Unfortunately, medical treatments for Alzheimer's disease and dementia have remained minimal for over 25 years, and with a growing aging population, Alzheimer's disease has become one of the greatest unmet medical needs in the world. There is hope on the horizon. Recently, two new intravenous medications, lecanemab and donanemab, have shown they can clear away toxic accumulations of the amyloid protein in Alzheimer's disease. One or both of these medications have been approved in the United States, European Union, United Kingdom, China, Japan, Mexico, Brazil and Australia. Yet they have not been approved in Canada. Canada is falling behind, and families are suffering. We need to make new Alzheimer's disease medications available to Canadians in a timely and accessible manner. Clinical trials researching lecanemab and donanemab demonstrated a 27 to 35 per cent slowing of cognitive decline in individuals with Alzheimer's disease versus a placebo, with greater benefit experienced the earlier in the disease process the treatment was started. The treatments slow the rate at which Alzheimer's disease worsens, though they do not fully stop or reverse the damage. Both lecanemab and donanemab remain under review by Health Canada and are not yet approved for use in Canada. The decision to approve these medications has been complex, as a slowing of cognitive deterioration by 27 per cent may not be viewed as enough of a benefit, especially when weighing against potential side-effects. Indeed, as these medications cross into the brain and trigger clearance of amyloid by the immune system, there can be development of swelling or bleeding in the brain. While most clinical trial participants who developed swelling or bleeding had no associated symptoms, three to six per cent experienced headache, dizziness, confusion or occasionally stroke-like symptoms. Often these symptoms were resolved when treatment stopped, though in rare cases they were permanent. In some ways, arrival of these medications ushers in a new era of Alzheimer's disease treatment, reminiscent of the approach we now take toward cancer: detection of disease at the earliest possible stage, and potential treatment with medications capable of serious side-effects. Canadians who have Alzheimer's disease deserve the chance to evaluate the potential benefits and side-effects of these new medications, to determine, for themselves and their families, if they wish to proceed to treatment. The decision process must include fully informed consent, guided by real-world results from patients across the world. Patient registries — collections of anonymous patient data — play a critical role in tracking benefits and side-effects of new medications over time. A registry for those treated with new Alzheimer's disease medications in Canada would be essential. At the end of July, Canada will welcome the global Alzheimer's disease clinical and research community to the Alzheimer's Association International Conference, held in Toronto this year. The message will be clear: Canada should provide the same treatment opportunities to its citizens as other jurisdictions around the world. The memories and autonomy destroyed by Alzheimer's disease continue to make it one of the greatest health challenges faced by Canadians. New anti-amyloid treatments are not a cure, though they represent desperately needed progress. They also represent hope that we will one day live a long and full life without the ravages of dementia. A long and full life, for ourselves and those we love. Dr. Andrew Frank is a cognitive neurologist at Bruyère Health and investigator at Bruyère Health Research Institute in Ottawa. Katherine C. Pearson is a professor of law and Arthur L. and Sandra S. Piccone Faculty Scholar at Dickinson Law, Pennsylvania State University, and the 2024-25 visiting research fellow at the University of Ottawa's Centre for Health Law, Policy and Ethics.
CTV News
5 days ago
- CTV News
Building Winnipeg's AI future
Building Winnipeg's AI future Professor Qian Liu shares how her team is using AI to tackle big challenges like Alzheimer's and why Winnipeg could be Canada's next AI hub.
Toronto Star
6 days ago
- Toronto Star
Hapbee Technologies Inc. Closes 2024 with Record Q4 Device Sales, Global Distribution Partnerships and Strategic Board Appointments
Fueled by a 198% surge in Q4 device sales revenue and a 200% increase in shipments, Hapbee's revitalized marketing strategy, expanded retail footprint, luxury spa partnerships, and high-profile Board additions have set the stage for accelerated growth heading into 2025. VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) — Hapbee Technologies Inc. (TSXV: HAPB | OTCQB: HAPBF), ('Hapbee' or the 'Company'), the digital wellness technology company pioneering the science of bio-streaming, is pleased to announce the financial and operational results for the fiscal year ending December 31, 2024.
